trending Market Intelligence /marketintelligence/en/news-insights/trending/zrrhmllwia9tume8grhj5q2 content esgSubNav
In This List

Biocept to raise $11.6M in rights offering

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Biocept to raise $11.6M in rights offering

Biocept Inc. said it expects to raise $11.6 million from a rights offering that expired Aug. 8.

The offering allowed eligible shareholders to buy a unit of the company for $1,000 each. The unit comprised a series A preferred stock that is convertible into common shares, and 220 warrants, each of which can be used to purchase an additional common stock for $4.53 apiece.

The warrants are exercisable within a five-year period after the issuance date.

The transaction is expected to close Aug. 13, subject to customary closing conditions.

San Diego-based Biocept is a molecular diagnostics company that provides assays for lung, breast, gastric, colorectal and prostate cancers as well as melanoma.

Maxim Group LLC and Dawson James Securities Inc. acted as co-dealer-managers in the offering, with Chardan and WestPark Capital serving as financial advisers.